Device/Diagnostics Quarterly Deal Statistics, Q3 2014
Executive Summary
Device financing decreased to $734 million in Q3, less than half the Q2 total, and the $4.9 billion in M&As was a sharp decline versus Q2. Diagnostics fundraising, at $399 million, showed a 31% drop from Q2, and Merck KGAA’s $16.7 billion buy of Sigma-Aldrich made up 96% of the Q3 M&A activity.
You may also be interested in...
Innovation And Under-Penetration Driving Global Vascular Access Markets
With an annual growth of almost 5%, the market for vascular access site repair products is attracting companies with innovative new products. Wider acceptance of new approaches to wound closure by interventionalists and the under-penetration in emerging Asian markets in particular are resulting in an uptake in the use of higher-tech devices and the emergence of local manufacturers.
Merck KGaA Buys Sigma-Aldrich To Boost Lab Business, Expand Footprint
By buying U.S.-based Sigma-Aldrich, the German conglomerate hopes to bolster its Millipore lab business, by giving the biopharma technology, tools and service provider added depth and global reach.
Danaher Will Top Dental Market With $2.2 Billion Nobel Biocare Buy
The deal will give Danaher the largest share of the dental implants market, and the overall dental industry, including sales of consumables and equipment approaching $3 billion.